Cameron Fine Sciences Limited approved a rights issue of 250 crores to stabilize working capital and support growth. Q2 EBITDA margin fell from 3.4% to 0.5%; management expects Q4 revenue of 600 crores and EBITDA of 60 crore plus.

5 source passages

Cameron Fine Sciences Limited Q2 and H1 FY27 Mornings Conference Call. At 250 crores, you can see we have not yet decided on the pricing. Obviously, this purpose of the issue is for augmenting working capital. this has percolated down and eaten up our EBITDA, which anyway was 3.4% has almost come down to 0.5% in this quarter. The turnaround, we expect the top line to be 600 crores, and the EBITDA to be 60 crore plus in Q4. Open the document at this passage

Aug 11

Earnings call

Q1 2027 earnings call AI summary on its way

May 26

Earnings call

Q4 2026 earnings call AI summary on its way

Showing 1–3 of 3 documents